Table 2.
Summary of the overall survival (OS) of patient cohorts grouped into cohorts expressing either high or low levels of connexin mRNA in non-small cell lung cancer (NSCLC) in general, lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC) compared with normal healthy tissue.
| Gene | Connexin | HR NSCLC | OS Change (Months) High Cx |
HR LUSC | OS Change (Months) High Cx |
HR LUAD | OS Change (Months) High Cx |
|---|---|---|---|---|---|---|---|
| GJA1 | Cx43 | 0.84 * | +19 | 0.78 | +24 | 0.64 * | +49 |
| GJA3 | Cx46 | 1.42 * | −41 | 0.77 | +27 | 1.48 * | −42 |
| GJA4 | Cx37 | 0.67 * | +43 | 0.83 | +22 | 0.67 * | +45 |
| GJA5 | Cx40 | 1.30 * | −23 | 1.20 | −4 | 1.86 * | −69 |
| GJA8 | Cx50 | 1.18 | −11 | 1.16 | −17 | 0.60 * | +59 |
| GJA10 | Cx62 | 1.20 | −28 | 0.77 | +24 | 1.62 * | −52 |
| GJB1 | Cx32 | 0.71 * | +31 | 1.38 | −24 | 0.60 * | +59 |
| GJB3 | Cx31 | 1.56 * | −37 | 1.27 | −21 | 2.39 * | −114 |
| GJB4 | Cx30.3 | 1.31 * | −23 | 1.18 | −15 | 1.88 * | −62 |
| GJB5 | Cx31.1 | 1.52 * | −36 | 1.12 | −12 | 1.63 * | −57 |
| GJB6 | Cx30 | 1.40 * | −38 | 0.75 | +29 | 0.82 | +11 |
| GJB2 | Cx26 | 1.49 * | −47 | 0.87 | +16 | 2.12 * | −56 |
| GJC1 | Cx45 | 0.73 * | +36 | 1.22 | −15 | 0.66 * | +37 |
| GJC2 | Cx47 | 1.13 | −6 | 0.81 | +27 | 1.45 * | −41 |
| GJC3 | Cx30.2 | 1.26 * | −27 | 0.78 | +8 | 1.76 * | −53 |
| GJD2 | Cx36 | 1.25 * | −18 | 1.14 | −11 | 2.13 * | −68 |
| GJD3 | Cx31.9 | 0.68 * | +39 | 0.66 * | +24 | 1.26 | −44 |
| GJD4 | Cx40.1 | 1.25 * | −22 | 0.83 | +27 | 1.49 * | −33 |
1.Abbreviations: HR, hazard ratio; OS, overall survival; NSCLC, non-small cell lung cancer; LUSC, squamous cell lung cancer; LUAD, adenocarcinoma lung cancer; Cx, connexin. 2. The table depicts the patient hazard ratio, where the cohort expressing high levels of connexin mRNA is either associated with better survival (depicted in green, HR less than 1, i.e., less chance of death, suggesting the connexin is a tumour suppressor) or with worse survival (red, HR greater than 1, i.e., higher chance of death, suggesting the connexin is pro-tumorigenic). The average change in survival (months) is the difference between the patient cohorts grouped as having high and low levels of connexins. Those associations with a significant statistical difference (p < 0.01) are in bold and marked with an asterisk *. Further detail and individual Kaplan-Meier curves can be seen in Supplementary Figure S3.